Sun Pharmaceutical Industries vs Aurobindo Pharma: Which Stock Should You Track

July 31, 2026
Posted by: Ankit Jaiswal
Category: News

Sun Pharmaceutical Industries vs Aurobindo Pharma: India’s largest pharmaceutical company by market cap vs a leading Indian generics exporter with a global manufacturing footprint. Sun Pharmaceutic…

Sun Pharmaceutical Industries vs Aurobindo Pharma is a comparison investors search for because the two companies represent genuinely different positions within Pharmaceuticals. This Sun Pharmaceutical Industries vs Aurobindo Pharma breakdown goes beyond generic labels and looks at real numbers: reach, products, the latest results each company has declared, and how each stock is positioned today. Understanding Sun Pharmaceutical Industries vs Aurobindo Pharma this way is more useful than a surface-level label, because it shows where each company actually stands rather than how it describes itself.

Table of Contents

Sun Pharmaceutical Industries vs Aurobindo Pharma: Reach and Market Position

In the Sun Pharmaceutical Industries vs Aurobindo Pharma comparison, Sun Pharmaceutical Industries stands out for India’s largest drugmaker by market cap, with a growing specialty pharmaceuticals franchise alongside its generics business. This scale gives Sun Pharmaceutical Industries a distinct position within Pharmaceuticals that shapes how it competes.

Click Here – Get Free Investment Predictions

Aurobindo Pharma, on the other hand, is built around a Hyderabad-based drugmaker exporting to over 150 countries through 27 global manufacturing and packing facilities. Comparing Sun Pharmaceutical Industries vs Aurobindo Pharma on reach alone shows two different growth strategies, not a single verdict.

Sun Pharmaceutical Industries vs Aurobindo Pharma: Key Products and Business Mix

Sun Pharmaceutical Industries’s business runs on generic drugs, specialty pharmaceuticals (including the Ilumya brand), and active pharmaceutical ingredients. This product mix is central to any Sun Pharmaceutical Industries vs Aurobindo Pharma comparison, since it explains where each company’s revenue actually comes from.

Aurobindo Pharma instead leans on generic drugs, active pharmaceutical ingredients, and biocatalysts through its AuroZymes division. The Sun Pharmaceutical Industries vs Aurobindo Pharma product comparison shows these are genuinely different businesses, not just different brand names in the same category.

Sun Pharmaceutical Industries vs Aurobindo Pharma: Latest Results

Looking at real numbers rather than claims, Sun Pharmaceutical Industries’s latest disclosed results show Q1 FY27 results were scheduled for July 31, 2026; analysts had projected around 11% topline growth with profit expected to decline 7-11% YoY on margin pressure from higher input costs. This is the clearest evidence available for the Sun Pharmaceutical Industries vs Aurobindo Pharma comparison on Sun Pharmaceutical Industries’s side.

Aurobindo Pharma’s latest disclosed results show FY2025 (latest full-year figures available) revenue of Rs 31,724 crore; prior-year quarterly results have shown swings tied to US sales and destocking cycles, with profit ranging from double-digit growth to double-digit declines across recent quarters. Weighing Sun Pharmaceutical Industries vs Aurobindo Pharma on actual results, rather than headline positioning, is what separates a useful comparison from a generic one.

Compare Sun Pharmaceutical Industries and Aurobindo Pharma Fundamentals on the Univest Screener

Sun Pharmaceutical Industries vs Aurobindo Pharma: Stock and Valuation

On the market side, Sun Pharmaceutical Industries is described as: Market cap around Rs 4,32,036 crore. Aurobindo Pharma is described as: Holds USFDA, UK MHRA and other major regulatory approvals across its facility network. The Sun Pharmaceutical Industries vs Aurobindo Pharma valuation gap often reflects how the market is pricing each company’s growth and risk profile differently.

Sun Pharmaceutical Industries vs Aurobindo Pharma: Quick Comparison Table

Parameter	Sun Pharmaceutical Industries	Aurobindo Pharma
Sector	Pharmaceuticals	Pharmaceuticals
Market position	India’s largest pharmaceutical company by market cap	a leading Indian generics exporter with a global manufacturing footprint
Reach	India’s largest drugmaker by market cap, with a growing specialty pharmaceuticals franchis	a Hyderabad-based drugmaker exporting to over 150 countries through 27 global manufacturin
Latest results	Q1 FY27 results were scheduled for July 31, 2026; analysts had projected around 11% topline growth w	FY2025 (latest full-year figures available) revenue of Rs 31,724 crore; prior-year quarterly results

Conclusion

Sun Pharmaceutical Industries vs Aurobindo Pharma ultimately comes down to two companies solving similar problems in different ways. Sun Pharmaceutical Industries brings India’s largest pharmaceutical company by market cap, while Aurobindo Pharma brings a leading Indian generics exporter with a global manufacturing footprint. Investors weighing Sun Pharmaceutical Industries vs Aurobindo Pharma should track both companies’ upcoming results and valuation gap rather than picking a side on reputation alone. This Sun Pharmaceutical Industries vs Aurobindo Pharma breakdown is a starting point, not a final verdict.

Download the Univest iOS App or Univest Android App to track Sun Pharmaceutical Industries and Aurobindo Pharma live price and get daily stock recommendations.

Disclaimer: Data and figures in this article are sourced from publicly available information, including company results filings and exchange data, and are current as of the time of writing. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions

What is the main difference between Sun Pharmaceutical Industries and Aurobindo Pharma?

Ans. The main difference in the Sun Pharmaceutical Industries vs Aurobindo Pharma comparison lies in scale and business mix. Sun Pharmaceutical Industries is built on India’s largest pharmaceutical company by market cap, while Aurobindo Pharma is positioned around a leading Indian generics exporter with a global manufacturing footprint.

How do Sun Pharmaceutical Industries and Aurobindo Pharma’s latest results compare?

Ans. Comparing Sun Pharmaceutical Industries vs Aurobindo Pharma on latest disclosed results: Sun Pharmaceutical Industries reported Q1 FY27 results were scheduled for July 31, 2026; analysts had projected around 11% topline growth with profit expected to decline 7-11% YoY, while Aurobindo Pharma reported FY2025 (latest full-year figures available) revenue of Rs 31,724 crore; prior-year quarterly results have shown swings tied to US sales and .

What sector do Sun Pharmaceutical Industries and Aurobindo Pharma operate in?

Ans. Sun Pharmaceutical Industries operates in Pharmaceuticals and Aurobindo Pharma operates in Pharmaceuticals. Even where the sectors overlap, the Sun Pharmaceutical Industries vs Aurobindo Pharma comparison shows different product mixes and market positions.

Should I invest in Sun Pharmaceutical Industries or Aurobindo Pharma?

Ans. Both Sun Pharmaceutical Industries and Aurobindo Pharma have distinct strengths within their space. Investors comparing Sun Pharmaceutical Industries vs Aurobindo Pharma should review the latest quarterly results, valuation and their own risk profile, and consult a financial advisor before deciding.

What are the key products of Sun Pharmaceutical Industries?

Ans. Sun Pharmaceutical Industries’s key products and business lines include generic drugs, specialty pharmaceuticals (including the Ilumya brand), and active pharmaceutical ingredients.

What are the key products of Aurobindo Pharma?

Ans. Aurobindo Pharma’s key products and business lines include generic drugs, active pharmaceutical ingredients, and biocatalysts through its AuroZymes division.

How do Sun Pharmaceutical Industries and Aurobindo Pharma compare on market position?

Ans. On market position, Sun Pharmaceutical Industries holds India’s largest pharmaceutical company by market cap, while Aurobindo Pharma holds a leading Indian generics exporter with a global manufacturing footprint. The Sun Pharmaceutical Industries vs Aurobindo Pharma comparison shows both companies lead in different ways rather than one being universally ahead.

News

Author: Ankit Jaiswal

Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.